TY - JOUR
T1 - Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
AU - Fermé, Christophe
AU - Eghbali, Houchingue
AU - Meerwaldt, Jacobus H.
AU - Rieux, Chantal
AU - Bosq, Jacques
AU - Berger, Françoise
AU - Girinsky, Théodore
AU - Brice, Pauline
AU - Van'T Veer, Mars B.
AU - Walewski, Jan A.
AU - Lederlin, Pierre
AU - Tirelli, Umberto
AU - Carde, Patrice
AU - Van Den Neste, Eric
AU - Gyan, Emmanuel
AU - Monconduit, Mathieu
AU - Diviné, Marine
AU - Raemaekers, John M M
AU - Salles, Gilles
AU - Noordijk, Evert M.
AU - Creemers, Geert Jan
AU - Gabarre, Jean
AU - Hagenbeek, Anton
AU - Reman, Oumédaly
AU - Blanc, Michel
AU - Thomas, José
AU - Vié, Brigitte
AU - Kluin-Nelemans, Johanna C.
AU - Viseu, Fernando
AU - Baars, Joke W.
AU - Poortmans, Philip
AU - Lugtenburg, Pieternella J.
AU - Carrie, Christian
AU - Jaubert, Jérôme
AU - Henry-Amar, Michel
PY - 2007/11/8
Y1 - 2007/11/8
N2 - BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. RESULTS: The median follow-up was 92 months. In the H8-F trial, the estimated 5-year eventfree survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P
AB - BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. RESULTS: The median follow-up was 92 months. In the H8-F trial, the estimated 5-year eventfree survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P
UR - http://www.scopus.com/inward/record.url?scp=35848959692&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35848959692&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa064601
DO - 10.1056/NEJMoa064601
M3 - Article
C2 - 17989384
AN - SCOPUS:35848959692
VL - 357
SP - 1916
EP - 1927
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 19
ER -